1160247-75-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1'-(tert-butoxycarbonyl)spiro[chromene-2,4'-piperidine]-4-carboxylic acid is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of biologically active molecules. The Boc group ensures that amine groups remain protected during the synthesis process, allowing for the creation of complex molecular structures with specific biological targets.
Used in Drug Discovery:
In the field of drug discovery, 1'-(tert-butoxycarbonyl)spiro[chromene-2,4'-piperidine]-4-carboxylic acid is utilized as a versatile building block to explore new chemical entities with potential therapeutic effects. Its structural features make it a candidate for the development of novel drugs with improved efficacy and selectivity.
Used in Chemical Biology:
1'-(tert-butoxycarbonyl)spiro[chromene-2,4'-piperidine]-4-carboxylic acid is employed in chemical biology as a modular component for constructing bioactive conjugates and probes. The carboxylic acid group allows for the attachment of various functional groups or other molecules, expanding the scope of research into the interactions between small molecules and biological systems.
Used in Organic Synthesis:
As a component in organic synthesis, 1'-(tert-butoxycarbonyl)spiro[chromene-2,4'-piperidine]-4-carboxylic acid is used as a precursor for the preparation of a range of organic compounds. Its unique spirocyclic structure and functional groups make it a valuable asset in the synthesis of complex organic molecules with specific applications in various industries.

Upstream product

• 1207163-67-4 tert-butyl 1'H-spiro[chromene-2,4'-piperidine]-1'-carboxylate 
• 1024604-94-1 tert-butyl 4-hydroxy-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxylate 
• 849928-22-9 tert-butyl 4-oxo-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 118-93-4 o-hydroxyacetophenone 

Relevant academic research and scientific papers

Whole cell screen based identification of spiropiperidines with potent antitubercular properties

Abstract Whole cell based screens to identify hits against Mycobacterium tuberculosis (Mtb), carried out under replicating and non-replicating (NRP) conditions, resulted in the identification of multiple, novel but structurally related spiropiperidines with potent antitubercular properties. These compounds could be further classified into three classes namely 3-(3-aryl-1,2,4-oxadiazol-5-yl)-1′-alkylspiro[indene-1,4′-piperidine] (abbr. spiroindenes), 4-(3-aryl-1,2,4-oxadiazol-5-yl)-1′-alkylspiro[chromene-2,4′-piperidine] (abbr. spirochromenes) and 1′-benzylspiro[indole-1,4′-piperidin]-2(1H)-one (abbr. spiroindolones). Spiroindenes showed ≥4 log10 kill (at 2-12 μM) on replicating Mtb, but were moderately active under non replicating conditions. Whole genome sequencing efforts of spiroindene resistant mutants resulted in the identification of I292L mutation in MmpL3 (Mycobacterial membrane protein Large), required for the assembly of mycolic acid into the cell wall core of Mtb. MIC modulation studies demonstrated that the mutants were cross-resistant to spirochromenes but not to spiroindolones. This Letter describes lead identification efforts to improve potency while reducing the lipophilicity and hERG liabilities of spiroindenes. Additionally, as deduced from the SAR studies, we provide insights regarding the new chemical opportunities that the spiroindolones can offer to the TB drug discovery initiatives.